Zusammenfassung
Hauptvertreter der Hypophysen- und Hypothalamushormone sind Wachstumshormon, Somatostatin, Gonadotropinpräparate und Vasopressinanaloga. Wachstumshormonpräparate wurden erneut etwas weniger verordnet, sind aber mit Kosten von 188 Mio. € weiterhin die umsatzstärkste Gruppe der Hypophysen- und Hypothalamushormone, gefolgt von Somatostatinanaloga (131 Mio. €) und Follitropinpräparaten (64 Mio. €). Die Verordnungskosten der Vasopressinanaloga für die Behandlung des zentralen Diabetes insipidus waren annähernd konstant (17 Mio. €).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Al-Inany HG, Youssef MA, Aboulghar M, Broekmans F, Sterrenburg M, Smit J, Abou-Setta AM (2011): Gonadotrophinreleasing hormone antagonists for assisted reproductive technology. Cochrane Database Syst Rev. 2011 May 11; (5): CD001750
Andrejak M, Tribouilloy C (2013): Drug-induced valvular heart disease: an update. Arch Cardiovasc Dis 106: 333–339
Choi J, Smitz J (2014): Luteinizing hormone and human chorionic gonadotropin: origins of difference. Mol Cell Endocrinol 383: 203–213
Deutsches IVF-Register (2017): Jahrbuch 2016. J Reproduktionsmed Endokrinol 14: 275–305
Fleseriu M (2011): Clinical efficacy and safety results for dose escalation of somatostatin receptor ligands in patients with acromegaly: a literature review. Pituitary 14: 184–193
International Recombinant Human Chorionic Gonadotropin Study Group (2001): Induction of ovulation in World Health Organization group II anovulatory women undergoing follicular stimulation with recombinant human follicle-stimulating hormone: a comparison of recombinant human chorionic gonadotropin (rhCG) and urinary hCG. Fertil Steril 75: 1111–1118
Liu H, Bravata DM, Olkin I, Nayak S, Roberts B, Garber AM, Hoffman AR (2007): Systematic review: the safety and efficacy of growth hormone in the healthy elderly. Ann Intern Med 146: 104–115
Melmed S (2006): Acromegaly. N Engl J Med 355: 2558–2573
Moore WV, Nguyen HJ, Kletter GB, Miller BS, Rogers D, Ng D, Moore JA, Humphriss E, Cleland JL, Bright GM (2016): A randomized safety and efficacy study of somavaratan (VRS-317), a long-acting rhGH, in pediatric growth hormone deficiency. J Clin Endocrinol Metab 101: 1091–1097
National Institute for Health and Care Excellence (2010): Human growth hormone (somatropin) for the treatment of growth failure in children. NICE technology appraisal guidance 188. Internet: http://www.nice.org.uk/guidance/ta188/resources/guidance-human-growthhormone-somatropin-for-the-treatment-of-growthfailure-in-children-pdf
National Institute for Health and Care Excellence (NICE) (2003): Human growth hormone (somatropin) in adults with growth hormone deficiency. Technology Appraisal 64. Internet: www.nice.org.uk/page.aspx?o=TA064guidance
Pacchiarotti A, Sbracia M, Frega A, Selman H, Rinaldi L, Pacchiarotti A (2010): Urinary hMG (Meropur) versus recombinant FSH plus recombinant LH (Pergoveris) in IVF: a multicenter, prospective, randomized controlled trial. Fertil Steril 94: 2467–2469
Perales-Puchalt A, Legro RS (2013): Ovulation induction in women with polycystic ovary syndrome. Steroids 78: 767–772
van der Lely AJ, Biller BM, Brue T, Buchfelder M, Ghigo E, Gomez R, Hey-Hadavi J, Lundgren F, Rajicic N, Strasburger CJ, Webb SM, Koltowska-Häggström M (2013): Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY. J Clin Endocrinol Metab 97: 1589–1597
van Wely M, Kwan I, Burt AL, Thomas J, Vail A, Van der Veen F, Al-Inany HG (2012): Recombinant versus urinary gonadotrophin for ovarian stimulation in assisted reproductive technology cycles. A Cochrane review. Hum Reprod Update 18: 111
Weiss NS, Nahuis M, Bayram N, Mol BW, Van der Veen F, van Wely M (2015): Gonadotrophins for ovulation induction in women with polycystic ovarian syndrome. Cochrane Database Syst Rev 2015 Sep 9; (9): CD010290
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature
About this chapter
Cite this chapter
Schwabe, U. (2018). Hypophysen- und Hypothalamushormone. In: Schwabe, U., Paffrath, D., Ludwig, WD., Klauber, J. (eds) Arzneiverordnungs-Report 2018. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-57386-0_30
Download citation
DOI: https://doi.org/10.1007/978-3-662-57386-0_30
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-57385-3
Online ISBN: 978-3-662-57386-0
eBook Packages: Medicine (German Language)